Hear that sigh of relief? Biogen Idec announced Tuesday that, as of mid-July, there had been no new reported cases of the rare brain disease linked with its multiple sclerosis drug Tysabri. That means no new cases since the drug was reintroduced last July under a U.S. program that monitors patients for any signs or symptoms of the disease, progressive multifocal leukoencephalopathy, or PML. This comes on the heels of Tysabri's re-instatement on the National Health Service formulary in the U.K last week. And more good news may be in the offing: An FDA committee backed Biogen's bid to make Tysabri an approved treatment for Crohn's diseaseÂ in early August. No word yet on whether the agency will give it the final nod.
- read this AP article
Tysabri: The comeback kid. Report
After reintroduction, Tysabri builds patient base. Report
FDA allows Tysabri back on market. Report